ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Phenotypic diversity in NAXE mutations.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- NAXD Deficiency: Heterogeneous Phenotypes and Positive Response to Niacin Treatment.Journal of inherited metabolic disease · 2026Article
- Progressive encephalopathy associated with novel compound heterozygous NAXE mutations in a Chinese patient: case report and literature review.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimNAD(P)HX epimerase (NAXE) gene mutations have been associated with early onset progressive encephalopathy. We present three patients with NAXE gene mutations and different initial manifestations. CASES: Patient(P)1 was a 30 month-old boy whose neurological regression started after an infection and progressed, ultimately leading to death one year later. His brain magnetic resonance imaging (MRI) findings were suggesting metabolic stroke. P2, nine year-old sister of P1, had mild developmental delay since birth, seizures after age 5 years and pellagra-like skin lesions. P3 was a 15 year old female presenting multifocal neurological signs progressing over months and leading to respiratory insufficiency. Her initial MRI was normal but inflammatory lesions appeared three months after the onset of symptoms. Laboratory investigations including biochemical, serological and metabolic tests, and brain biopsy were unrevealing. Clinical presentation of P1 and P3 initially suggested autoimmune neurological disease, but no response to immunotherapy was obtained. Two different types of variants c.641T > G; p.Ile214Ser and c.128 C > A, p.Ser43* were detected in NAXE in these patients' two unrelated families. All patients were given mitochondrial cocktail including niacin. DISCUSSION: NAXE plays an important role in the electron donors for the mitochondrial respiratory chain. Mutations result in accumulation of toxic metabolites, disruption of energy production, and possibly cell death. P1-3 displayed different ages of onset, different clinical courses and MRI findings unreported previously, suggesting immune-mediated encephalitis and metabolic stroke in P1, and an inflammatory process in P3. NAXE mutations should be considered in progressive central nervous system symptoms.
Indexed as
Identifiers
39937421What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.